Havrix Junior (Hepatitis A Virus (Inactivated ) Adsorbed On Aluminium Hydroxide Hydrated Produced On Human Diploid)

Havrix Junior is indicated for the prevention of hepatitis A infection in children and adolescents.

• Primary prophylaxis for hepatitis A in children 12 months and older.
• Completion of a two‑dose series, spaced 6 to 12 months apart, as recommended by local health authorities.
• Use in travelers to regions where hepatitis A is endemic, when administered according to travel schedule.
• Administration to individuals with chronic liver disease to reduce risk of severe hepatitis A.
• Optional use in outbreak settings to quickly increase community immunity.

The safety profile of Havrix Junior reflects typical vaccine reactions, most of which are mild and transient.

Common

• Pain, redness, or swelling at the injection site.
• Low‑grade fever within 24‑48 hours after vaccination.
• Headache or mild fatigue lasting a day or two.
• Temporary loss of appetite or mild gastrointestinal upset.
• Mild muscle aches or joint stiffness.
• Localized bruising or tenderness at the injection site.

Serious

• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Neurological events including Guillain‑Barré syndrome (rare).
• Persistent high fever or severe systemic illness.
• Seizures or convulsions (extremely rare).

Healthcare providers should assess individual health status before administering Havrix Junior and follow recommended precautions to ensure safe use.

• Verify the child is at least 12 months old before vaccination.
• Defer vaccination in persons with known severe allergic reaction to any vaccine component, including aluminium hydroxide.
• Postpone administration if the child has an acute moderate or severe illness with fever.
• Consider a delayed schedule for children receiving immunoglobulin or blood products.
• Counsel caregivers about expected mild reactions and when to seek medical attention.
• Document any previous hepatitis A vaccination to avoid unnecessary repeat dosing.

Havrix Junior may interact with other medical products; understanding these interactions helps optimize immunisation timing and safety.

Avoid

• Concurrent administration with live viral vaccines (e.g., measles‑mumps‑rubella) is generally avoided unless required by schedule.
• Simultaneous receipt of immunoglobulin or blood products that contain anti‑hepatitis A antibodies may reduce vaccine effectiveness.
• Avoid administration during febrile illness to prevent confusion of symptoms.

Use with caution

• Use with caution in children receiving immunosuppressive therapy, as response may be diminished.
• Consider spacing from high‑dose steroids or chemotherapy to improve antibody development.
• Monitor closely if the child is on antipyretic medication, as it may mask fever after vaccination.
• Use with caution when the child is on antiplatelet agents, monitoring for injection‑site bleeding.